CNO (CNO) Q4 2025: Medicare Supplement Sales Surge 92% as Product Mix Shifts
CNO’s Q4 2025 revealed a decisive pivot in product mix, highlighted by a 92% surge in Medicare Supplement sales, as the company capitalizes on shifting consumer preferences and maintains robust capital deployment. Management’s focus on agent productivity, disciplined investment strategy, and a resilient middle-income customer base underpin continued confidence in multi-year earnings growth despite mounting macro headwinds. Investors should watch for evolving Medicare market dynamics and the impact of tech modernization investments on future operating leverage.
Summary
- Medicare Supplement Outpaces Market: CNO capitalized on industry-wide shifts, driving record growth in core insurance products.
- Agent Productivity Emphasized: Leadership prioritizes productivity gains over headcount, aiming for operational leverage.
- Capital Flexibility Maintained: Strong free cash flow and disciplined capital deployment support sustained growth and resilience.
Business Overview
CNO Financial Group is a U.S.-focused insurance holding company targeting the underserved middle-income market through two main divisions: Consumer (Bankers Life, direct-to-consumer, brokerage, and advisory) and Worksite (employer-sponsored voluntary benefits). CNO generates revenue by selling life, health, Medicare supplement, annuity, and worksite insurance products, as well as asset management and advisory services. Its exclusive captive agent model, last mile captive agent distribution, is designed to build long-term relationships and deliver cross-selling opportunities, forming a durable competitive advantage in the middle-market insurance landscape.
Performance Analysis
CNO delivered its fourteenth consecutive quarter of sales growth, with record new annualized premium (NAP) up 15% for the full year and standout Q4 Medicare Supplement sales up 92%. The Consumer division saw double-digit growth across life, supplemental health, and annuities, while direct-to-consumer life sales rose 20% as digital and third-party channels now drive over 70% of D2C volume, reducing dependence on traditional TV marketing.
The Worksite division posted its strongest year ever, with insurance sales up 15% and agent count up 7%, powered by geographic expansion and new group client wins. Operating earnings per share excluding significant items exceeded guidance, supported by strong insurance margins, expanding book yield, and disciplined expense management, as the expense ratio improved to 18.9%. Share repurchases totaled $320 million, reducing share count by 8%, while the risk-based capital ratio ended at 380%, well above regulatory thresholds.
- Medicare Mix Shift: Medicare Supplement NAP up 49% for the year, offsetting a 3% decline in Medicare Advantage policies as consumer preferences evolve.
- Investment Yield Stability: New money rates topped 6% for the twelfth straight quarter, sustaining portfolio quality and net investment income growth.
- Expense Leverage: Improved operating leverage drove the expense ratio below guidance, even as CNO invested in tech modernization and agent productivity.
Capital deployment remains disciplined, with a focus on buybacks, dividend increases, and measured risk appetite. Management’s guidance for 2026 points to continued operating earnings growth, stable capital metrics, and ongoing investment in technology and core distribution.
Executive Commentary
"Our exclusive middle market focus and our last mile captive agent distribution model create our durable competitive moat. This difficult to replicate model is a clear competitive advantage and a catalyst for profitable growth."
Gary Bujwani, Chief Executive Officer
"Operating return on equity excluding significant items was 11.4%, reflecting significant improvement from the 10% run rate return on equity in 2024 and good progress toward our 12% target ROE in 2027."
Paul McDonough, Chief Financial Officer
Strategic Positioning
1. Medicare Product Realignment
Medicare Supplement now anchors CNO’s growth, with a 92% quarterly surge and 49% annual growth, as industry-wide benefit cuts in Medicare Advantage drive consumers to more stable supplement offerings. This shift increases cross-sell potential and deepens client relationships, especially with higher net-worth seniors.
2. Agent Productivity Over Expansion
Leadership’s primary operational lever is agent productivity, not simply count. While producing agent count continues to rise, management emphasizes technology-driven productivity gains and targeted recruiting, improving both efficiency and sales momentum.
3. Digital Channel Diversification
Direct-to-consumer sales are increasingly digital, with over 70% of leads now sourced from web, digital, and third-party channels. This reduces customer acquisition cost volatility and broadens reach beyond traditional TV marketing, supporting sustainable growth in life products.
4. Capital and Risk Management Discipline
CNO maintains a robust capital position, with a 380% risk-based capital ratio and liquidity well above minimum thresholds. The company’s measured approach to share repurchases and reinsurance transactions with its Bermuda affiliate preserves flexibility for future growth and regulatory compliance.
5. Technology Modernization Initiative
A multi-year $170 million tech investment is underway, with $20 million deployed in 2025 and $75 million planned for 2026. Management expects this to enhance agent tools, operational efficiency, and long-term margin expansion, though near-term expense ratios will reflect the investment ramp.
Key Considerations
CNO’s strategic execution in 2025 reflected a balance of growth, risk management, and operational efficiency, while positioning for future demographic and regulatory shifts.
Key Considerations:
- Medicare Advantage Headwinds Intensify: Ongoing benefit cuts and carrier retrenchment in Medicare Advantage create both risk and opportunity in product mix and distribution fee stability.
- Demographic Tailwinds Remain Strong: With 11,000 Americans turning 65 daily, demand for Medicare products is expected to rise for the next decade, supporting core business growth.
- Expense Ratio Management: Sustained improvement in operating leverage is key as tech investments ramp and revenue mix shifts toward lower-margin products.
- Investment Portfolio Caution: Management resists chasing yield in tight spread environments, prioritizing portfolio quality and risk-adjusted returns over short-term gains.
- Capital Deployment Flexibility: Excess capital above targets will likely continue to be returned to shareholders, but disciplined pacing is expected given market and regulatory uncertainties.
Risks
Macroeconomic uncertainty, including layoffs and consumer caution, could pressure discretionary product sales such as annuities and life insurance, even as Medicare-related demand remains resilient. Medicare Advantage volatility poses risk to distribution fee income, while regulatory scrutiny and market conditions could impact the cadence of reinsurance transactions and capital deployment. Investment income could soften if alternative asset yields decline or credit risk rises, though management’s conservative approach mitigates tail risk.
Forward Outlook
For Q1 2026, CNO guided to:
- Operating earnings per share between $4.25 and $4.45 for the year, representing 8% growth at the midpoint.
- Expense ratio of 18.8% to 19.2%, with seasonality expected to start higher in Q1 and trend lower through the year.
For full-year 2026, management maintained guidance:
- Risk-based capital ratio of 360% to 390%.
- Free cash flow of $200 to $250 million, net of tech investment.
Management cited stable macro assumptions, continued sales momentum, and disciplined capital deployment as key drivers, while acknowledging ongoing headwinds in discretionary segments and Medicare Advantage.
- Tech modernization spend will increase, temporarily impacting expense ratios.
- Medicare Supplement expected to remain a growth engine as demographic trends persist.
Takeaways
CNO’s Q4 2025 results underscore the strategic importance of product mix agility, agent productivity, and disciplined capital management as the company navigates shifting industry and macro dynamics.
- Medicare Supplement Surges: A 92% quarterly increase in MedSupp sales demonstrates CNO’s ability to pivot as Medicare Advantage headwinds intensify, reinforcing its relevance to the aging population.
- Operational Leverage Focus: Management’s prioritization of agent productivity and tech investment is driving sustainable margin improvement and positioning CNO for scalable growth.
- Watch for Fee Pressure and Tech ROI: Investors should monitor how ongoing Medicare Advantage disruption and tech modernization expenses affect near-term earnings, with longer-term upside if CNO’s model continues to deliver cross-sell and retention benefits.
Conclusion
CNO’s 2025 performance confirms its durable middle-market franchise, with record insurance sales and strong capital stewardship offsetting emerging macro and Medicare-specific risks. The company’s focus on productivity, digital diversification, and prudent investment positions it for continued growth, though investors must watch for near-term headwinds in discretionary products and fee income volatility.
Industry Read-Through
CNO’s results highlight a decisive industry pivot away from Medicare Advantage and toward Medicare Supplement, as regulatory and carrier actions reshape senior market dynamics. Captive distribution models and digital lead diversification are proving effective in maintaining growth amid consumer and channel volatility. Disciplined capital and investment management remain critical as insurers face compressed spreads and unpredictable macro conditions. For peers, the quarter underscores the value of product mix flexibility, operational efficiency, and a cautious approach to risk in both insurance and asset management portfolios.